更新口服恩曲他滨/替诺福韦二吡呋酯用于顺性别女性人类免疫缺陷病毒暴露前预防的依从性-反应。
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
机构信息
Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2023 May 24;76(10):1850-1853. doi: 10.1093/cid/ciad021.
Abstract
Using intraerythrocytic tenofovir-diphosphate data from the emtricitabine/tenofovir disoproxil fumarate arms of HIV Prevention Trials Network (HPTN) 083 (men) and HPTN 084 (women), approximately 99% efficacy was achieved at a lower adherence threshold in HPTN 083 (≥2 doses/week) compared with HPTN 084 (daily), suggesting higher adherence is necessary for women vs men.
摘要
利用艾滋病毒预防试验网络（HPTN）083（男性）和 HPTN 084（女性）中恩曲他滨/替诺福韦二吡呋酯制剂手臂内的替诺福韦二磷酸数据，在 HPTN 083（每周≥2 剂）中，与 HPTN 084（每日）相比，较低的依从性阈值达到了约 99%的功效，这表明女性比男性需要更高的依从性。
相似文献
1
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.更新口服恩曲他滨/替诺福韦二吡呋酯用于顺性别女性人类免疫缺陷病毒暴露前预防的依从性-反应。
Clin Infect Dis. 2023 May 24;76(10):1850-1853. doi: 10.1093/cid/ciad021.
2
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.长效卡替拉韦与每日口服替诺福韦酯富马酸二吡呋酯/恩曲他滨相比预防无对照研究 1 年后与男性发生性行为的顺性别男性和跨性别女性感染 HIV 的疗效和安全性：HPTN 083 随机对照 2b 期和 3 期试验的二次分析。
Lancet HIV. 2023 Dec;10(12):e767-e778. doi: 10.1016/S2352-3018(23)00261-8. Epub 2023 Nov 9.
3
Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.顺性别女性中恩曲他滨和富马酸替诺福韦二吡呋酯暴露前预防的依从性和 HIV 保护阈值：系统评价。
Curr HIV/AIDS Rep. 2024 Oct;21(5):264-281. doi: 10.1007/s11904-024-00705-0. Epub 2024 Aug 9.
4
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.基于 HPTN 083 和 HPTN 084 试验的南非长效注射型卡替拉韦与口服暴露前预防的相对成本效益：模型经济评估和阈值分析。
Lancet HIV. 2022 Dec;9(12):e857-e867. doi: 10.1016/S2352-3018(22)00251-X. Epub 2022 Nov 7.
5
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和替诺福韦二吡呋酯用于 HIV-1 暴露前预防的长期安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的第 96 周结果。
Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0.
6
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.恩曲他滨和替诺福韦酯二甲苯磺酸盐在顺性别女性中的 HIV 暴露前预防。
JAMA. 2024 Mar 19;331(11):930-937. doi: 10.1001/jama.2024.0464.
7
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.在接受注射用卡替拉韦或替诺福韦艾拉酚胺/恩曲他滨用于 HIV 预防的女性中人类免疫缺陷病毒（HIV）感染的特征：HPTN 084。
J Infect Dis. 2022 May 16;225(10):1741-1749. doi: 10.1093/infdis/jiab576.
8
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.部分依从性的顺性别女性中口服暴露前预防 HIV 效果的估计。
Nat Med. 2023 Nov;29(11):2748-2752. doi: 10.1038/s41591-023-02564-5. Epub 2023 Oct 5.
9
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.美国男女性人群中，含替诺福韦二吡呋酯富马酸酯和/或马拉维若和/或恩曲他滨的候选 PrEP 方案的骨骼变化：HPTN 069/ACTG A5305。
J Antimicrob Chemother. 2022 Feb 2;77(2):500-506. doi: 10.1093/jac/dkab400.
10
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.长效注射用卡替拉韦用于 HIV 暴露前预防的疗效、安全性、耐受性和药代动力学：HPTN 083 试验的二次分析。
Lancet HIV. 2023 Nov;10(11):e703-e712. doi: 10.1016/S2352-3018(23)00200-X. Epub 2023 Sep 29.
引用本文的文献
1
Are Sex-Specific Cutoffs Needed With a Next-Generation Urine Tenofovir Lateral Flow Assay for Antiretroviral Adherence Monitoring?下一代尿液替诺福韦侧向流动分析法用于抗逆转录病毒治疗依从性监测时是否需要特定性别的临界值？
Open Forum Infect Dis. 2025 Aug 21;12(9):ofaf512. doi: 10.1093/ofid/ofaf512. eCollection 2025 Sep.
2
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.恩曲他滨替诺福韦酯用于顺性别女性暴露前预防艾滋病毒感染的依从性阈值：一项随机直接观察给药研究。
PLoS Med. 2025 Sep 9;22(9):e1004732. doi: 10.1371/journal.pmed.1004732. eCollection 2025 Sep.
3
Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV.注射用长效来那卡帕韦暴露前预防（PrEP）抗HIV的药代动力学、药效学、疗效及耐药性选择
medRxiv. 2025 Aug 28:2025.08.26.25334527. doi: 10.1101/2025.08.26.25334527.
4
The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study.加拿大艾伯塔省成人艾滋病病毒暴露前预防的真实世界有效性：一项基于人群的回顾性队列研究。
Can J Infect Dis Med Microbiol. 2025 Aug 10;2025:9340622. doi: 10.1155/cjid/9340622. eCollection 2025.
5
Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment.用于评估暴露前预防依从性的红细胞内替诺福韦二磷酸酯和恩曲他滨三磷酸酯解读建议。
J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003715.
6
Dosing forgiveness of oral PrEP for cisgender women remains uncertain.对于顺性别女性口服暴露前预防药物（PrEP）的剂量豁免仍不确定。
J Int AIDS Soc. 2025 May;28(5):e26496. doi: 10.1002/jia2.26496.
7
Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025.2025年美国疾病控制与预防中心关于性接触、注射吸毒或其他非职业性接触HIV后抗逆转录病毒暴露后预防的建议
MMWR Recomm Rep. 2025 May 8;74(1):1-56. doi: 10.15585/mmwr.rr7401a1.
8
High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort.非洲年轻女性中近期通过即时检验尿替诺福韦检测及依从性咨询实现的高暴露前预防药物依从性：INSIGHT队列研究结果
J Int AIDS Soc. 2024 Dec;27(12):e26389. doi: 10.1002/jia2.26389.
9
Updated guidelines on HIV post-exposure prophylaxis: continued efforts towards increased accessibility.HIV 暴露后预防指南更新：持续努力提高可及性。
J Int AIDS Soc. 2024 Nov;27(11):e26393. doi: 10.1002/jia2.26393.
10
Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant.利用伊斯拉特韦对 HIV-1 的预防效果和毒性进行建模表明，口服给药没有优势，但作为皮下植入物有一定前景。
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1693-1706. doi: 10.1002/psp4.13212. Epub 2024 Aug 20.
本文引用的文献
1
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.卡博特韦用于女性艾滋病毒 1 型的预防：来自 HPTN 084 的结果，一项 3 期、随机临床试验。
Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1.
2
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.在接受注射用卡替拉韦或替诺福韦艾拉酚胺/恩曲他滨用于 HIV 预防的女性中人类免疫缺陷病毒（HIV）感染的特征：HPTN 084。
J Infect Dis. 2022 May 16;225(10):1741-1749. doi: 10.1093/infdis/jiab576.
3
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.卡博特韦用于预防顺性别男性和跨性别女性中的 HIV。
N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016.
4
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.长效卡替拉韦用于健康成年人 HIV 暴露前预防的多室药代动力学评价。
Br J Clin Pharmacol. 2022 Feb;88(4):1667-1678. doi: 10.1111/bcp.14980. Epub 2021 Jul 29.
5
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.接受注射用卡博特韦预防艾滋病毒的男同性恋和顺性别男性及跨性别女性中人类免疫缺陷病毒（HIV）感染的特征：HPTN 083研究
J Infect Dis. 2021 Nov 16;224(9):1581-1592. doi: 10.1093/infdis/jiab152.
6
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.撒哈拉以南非洲地区接受每日观察性暴露前预防的妊娠和产后青少年和年轻女性的干血斑中替诺福韦二磷酸浓度。
Clin Infect Dis. 2021 Oct 5;73(7):e1893-e1900. doi: 10.1093/cid/ciaa1872.
7
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.一种转化药理学方法，用于预测使用富马酸替诺福韦二吡呋酯联合或不联合恩曲他滨对男性和女性进行暴露前预防艾滋病毒的结果。
J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.
8
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.按需暴露前预防治疗在 HIV-1 感染高危男性中的应用。
N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.
9
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.一种长效整合酶抑制剂可保护雌性猕猴免受反复高剂量经阴道感染猴免疫缺陷病毒/猴-人免疫缺陷病毒嵌合体（SHIV）的攻击。
Sci Transl Med. 2015 Jan 14;7(270):270ra4. doi: 10.1126/scitranslmed.3010298.
10
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.单药替诺福韦与恩曲他滨联合替诺福韦用于HIV-1暴露前预防：一项随机、双盲、3期试验数据的更新
Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.
Zotero 插件